Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
Fernando J Martinez,1 Klaus F Rabe,2 Brian J Lipworth,3 Samir Arora,4 Martin Jenkins,5 Ubaldo J Martin,6 Colin Reisner6,7 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA; 2Department of Pneumonology, LungenClinic Grosshansdorf and Christian-Albrechts Univ...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-01-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/glycopyrrolateformoterol-fumarate-metered-dose-inhaler-improves-lung-f-peer-reviewed-article-COPD |
id |
doaj-3d998bb874d340d0baaceb739ae6c322 |
---|---|
record_format |
Article |
spelling |
doaj-3d998bb874d340d0baaceb739ae6c3222020-11-25T02:26:26ZengDove Medical PressInternational Journal of COPD1178-20052020-01-01Volume 159910651000Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE StudiesMartinez FJRabe KFLipworth BJArora SJenkins MMartin UJReisner CFernando J Martinez,1 Klaus F Rabe,2 Brian J Lipworth,3 Samir Arora,4 Martin Jenkins,5 Ubaldo J Martin,6 Colin Reisner6,7 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA; 2Department of Pneumonology, LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; 3Division of Molecular and Clinical Medicine, Scottish Centre for Respiratory Research, Ninewells Hospital, University of Dundee, Dundee, Scotland, UK; 4Aventiv Research Inc., Columbus, OH, USA; 5Global Medicines Development, AstraZeneca, Cambridge, UK; 6Research and Development, AstraZeneca, Gaithersburg, MD, USA; 7R&D Biopharmaceuticals, AstraZeneca, Morristown, NJ, USACorrespondence: Fernando J MartinezJoan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, 525 E 68th Street, Room M-522, Box 130, New York, NY 10065, USATel +1646 962 2748Email fjm2003@med.cornell.eduBackground: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2, and -4 studies to evaluate the efficacy and safety of the dual bronchodilator fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-suspension delivery technology, in GOLD category A patients with moderate-to-very severe COPD.Materials and Methods: PINNACLE-1, -2, and -4 were Phase III, randomized, double-blind, parallel-group, multicenter studies (NCT01854645, NCT01854658, and NCT02343458). Patients received 24 weeks’ treatment with GFF MDI 18/9.6 μg, glycopyrrolate (GP) MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or placebo MDI twice daily. GOLD category A patients were identified based on a COPD Assessment Test score of 1), peak change from baseline in FEV1 within 2 hrs post-dose, and adverse events (AEs).Results: The pooled intent-to-treat population comprised 729 GOLD category A patients. GFF MDI significantly improved morning pre-dose trough FEV1 at Week 24 versus GP MDI, FF MDI, and placebo MDI (least squares mean [LSM] differences 54 mL, 62 mL, and 188 mL, respectively; all p≤0.0053), and peak FEV1 at Week 24 versus GP MDI, FF MDI, and placebo MDI (LSM differences 124 mL, 104 mL, and 307 mL, respectively; all p<0.0001). Improvements over 24 weeks were comparable to at Week 24. The AE profile of GFF MDI in GOLD category A patients was similar to monocomponents and placebo MDI.Conclusion: GFF MDI significantly improved lung function versus monocomponents and placebo MDI in GOLD category A patients with moderate-to-very severe COPD, with no unexpected safety findings.Keywords: β2-agonist, bronchodilator, COPD, co-suspension delivery technology, lung function, muscarinic antagonisthttps://www.dovepress.com/glycopyrrolateformoterol-fumarate-metered-dose-inhaler-improves-lung-f-peer-reviewed-article-COPDβ2-agonistbronchodilatorcopdco-suspension delivery technologylung functionmuscarinic antagonist |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martinez FJ Rabe KF Lipworth BJ Arora S Jenkins M Martin UJ Reisner C |
spellingShingle |
Martinez FJ Rabe KF Lipworth BJ Arora S Jenkins M Martin UJ Reisner C Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies International Journal of COPD β2-agonist bronchodilator copd co-suspension delivery technology lung function muscarinic antagonist |
author_facet |
Martinez FJ Rabe KF Lipworth BJ Arora S Jenkins M Martin UJ Reisner C |
author_sort |
Martinez FJ |
title |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_short |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_full |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_fullStr |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_full_unstemmed |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_sort |
glycopyrrolate/formoterol fumarate metered dose inhaler improves lung function versus monotherapies in gold category a patients with copd: pooled data from the phase iii pinnacle studies |
publisher |
Dove Medical Press |
series |
International Journal of COPD |
issn |
1178-2005 |
publishDate |
2020-01-01 |
description |
Fernando J Martinez,1 Klaus F Rabe,2 Brian J Lipworth,3 Samir Arora,4 Martin Jenkins,5 Ubaldo J Martin,6 Colin Reisner6,7 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA; 2Department of Pneumonology, LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; 3Division of Molecular and Clinical Medicine, Scottish Centre for Respiratory Research, Ninewells Hospital, University of Dundee, Dundee, Scotland, UK; 4Aventiv Research Inc., Columbus, OH, USA; 5Global Medicines Development, AstraZeneca, Cambridge, UK; 6Research and Development, AstraZeneca, Gaithersburg, MD, USA; 7R&D Biopharmaceuticals, AstraZeneca, Morristown, NJ, USACorrespondence: Fernando J MartinezJoan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, 525 E 68th Street, Room M-522, Box 130, New York, NY 10065, USATel +1646 962 2748Email fjm2003@med.cornell.eduBackground: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2, and -4 studies to evaluate the efficacy and safety of the dual bronchodilator fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-suspension delivery technology, in GOLD category A patients with moderate-to-very severe COPD.Materials and Methods: PINNACLE-1, -2, and -4 were Phase III, randomized, double-blind, parallel-group, multicenter studies (NCT01854645, NCT01854658, and NCT02343458). Patients received 24 weeks’ treatment with GFF MDI 18/9.6 μg, glycopyrrolate (GP) MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or placebo MDI twice daily. GOLD category A patients were identified based on a COPD Assessment Test score of 1), peak change from baseline in FEV1 within 2 hrs post-dose, and adverse events (AEs).Results: The pooled intent-to-treat population comprised 729 GOLD category A patients. GFF MDI significantly improved morning pre-dose trough FEV1 at Week 24 versus GP MDI, FF MDI, and placebo MDI (least squares mean [LSM] differences 54 mL, 62 mL, and 188 mL, respectively; all p≤0.0053), and peak FEV1 at Week 24 versus GP MDI, FF MDI, and placebo MDI (LSM differences 124 mL, 104 mL, and 307 mL, respectively; all p<0.0001). Improvements over 24 weeks were comparable to at Week 24. The AE profile of GFF MDI in GOLD category A patients was similar to monocomponents and placebo MDI.Conclusion: GFF MDI significantly improved lung function versus monocomponents and placebo MDI in GOLD category A patients with moderate-to-very severe COPD, with no unexpected safety findings.Keywords: β2-agonist, bronchodilator, COPD, co-suspension delivery technology, lung function, muscarinic antagonist |
topic |
β2-agonist bronchodilator copd co-suspension delivery technology lung function muscarinic antagonist |
url |
https://www.dovepress.com/glycopyrrolateformoterol-fumarate-metered-dose-inhaler-improves-lung-f-peer-reviewed-article-COPD |
work_keys_str_mv |
AT martinezfj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT rabekf glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT lipworthbj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT aroras glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT jenkinsm glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT martinuj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT reisnerc glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies |
_version_ |
1724847146327343104 |